WuXi AppTec Third Quarterly 2025 Results October 27, 2025 603259.SH / 2359.HK 1 Forward-Looking Statements This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as "expects", "plans", "will", "estimates", "projects", "intends", or words of similar meaning. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as ...

Group 1 - Zhang Xuefeng's return to live streaming emphasizes the potential of liberal arts majors, stating they have significant opportunities [3] - His previous controversial statements, such as "news is useless" and "liberal arts are all service industries," sparked widespread debate [4][3] - Zhang's social media accounts, with a combined following of over 65 million, were previously suspended, highlighting his influence [3] Group 2 - The birth rate in China for 2024 is projected at 9.54 million, an increase of 520,000 from 2023, with a birth rate of 6.77‰, up by 0.38‰ [4] - The report indicates that 14 provinces have birth rates above the national average, with 10 provinces exceeding 8‰, primarily in western and southern regions [4] Group 3 - Morgan Stanley plans to allow institutional clients to use Bitcoin and Ethereum as collateral, indicating a shift towards integrating cryptocurrencies into traditional finance [14] - The company is responding to the growing demand for cryptocurrency services among institutional investors [14] Group 4 - Porsche reported a significant loss of €966 million in Q3, leading to a 99% drop in sales profit year-on-year, prompting organizational restructuring and layoffs [18] - The company's revenue for the first nine months of the year was approximately €26.86 billion, a 6% decline compared to the previous year [18] Group 5 - WuXi AppTec reported a net profit of ¥12.076 billion for the first three quarters, marking an 84.84% year-on-year increase, with revenue growth of 18.61% [18]

外资态度来看，本期较上一季度持股减少的外资基金共计1个，即香港中央结算有限公司，持股减少占 比达1.77%。本期较上一季度新披露的外资机构有 1 家 ，即G&C VII Limited。 2025年10月27日，药明康德(603259.SH)发布2025年第三季报。截至2025年10月26日，共有55个机构投 资者披露持有药明康德A股股份，合计持股量达8.52亿股，占药明康德总股本的28.73%。其中，前十大 机构投资者包括香港中央结算有限公司、G&C VI Limited、G&C IV Hong Kong Limited、北京中民银孚 投资管理有限公司-嘉兴宇祥投资合伙企业(有限合伙)、G&C V Limited、中国工商银行-上证50交易型开 放式指数证券投资基金、中国工商银行股份有限公司-华泰柏瑞沪深300交易型开放式指数证券投资基 金、G&C VII Limited、上海厚燊投资中心(有限合伙)、创新药，前十大机构投资者合计持股比例达 28.17%。相较于上一季度，前十大机构持股比例合计下跌了4.23个百分点。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 公募基金方面，本期 ...

【财经日历】 09:30 中国9月规模以上工业企业利润年率 美国股市上周五显著上扬，道琼斯工业平均指数上涨472.51点，收于47207.12点，涨幅1.01%；标普500指数上涨0.79%，收于6791.69点；纳斯达克指数上涨 1.15%，收于23204.87点，三大指数均创下收盘历史新高。 科技七巨头多数收高，谷歌A上涨2.70%，英伟达上涨2.25%，亚马逊上涨1.41%，苹果上涨1.25%，微软与Meta Platforms均上涨0.59%；特斯拉逆势下跌 3.40%。 科技成长充分蓄势后，中长期仍将维持上行格局。 中概股整体走高，纳斯达克中国金龙指数上涨0.27%，周累计涨幅达2.4%。 国际油价小幅回落，WTI原油收于每桶61.50美元，跌幅0.47%；布伦特原油收于65.20美元，跌幅0.14%。 COMEX黄金期货微跌0.19%，报4137.8美元/盎司。 ►►据新华社，当地时间10月25日至26日，中美经贸中方牵头人、国务院副总理何立峰与美方牵头人、美国财政部长贝森特和贸易代表格里尔在马来西亚吉 隆坡举行中美经贸磋商。双方以今年以来两国元首历次通话重要共识为引领，围绕美对华海事物流和造船业 ...

Group 1 - Shuyou Shen plans to raise no more than 1.253 billion yuan through a private placement to support innovative drug research and supplement working capital [1] - The issuance will involve no more than 143 million shares, with the price set at no less than 80% of the average trading price over the previous 20 trading days [1] Group 2 - WuXi AppTec reported a 84.84% year-on-year increase in net profit for the first three quarters, reaching 12.076 billion yuan, driven by a focus on CRDMO business and gains from selling shares in WuXi XDC Cayman Inc. [2] - The company achieved a revenue of 32.857 billion yuan, marking an 18.61% year-on-year growth [2] Group 3 - Wanfu Bio's net profit for the first three quarters decreased by nearly 70%, with a revenue of 1.69 billion yuan, down 22.52% year-on-year [3] - The third quarter revenue was 445 million yuan, a decline of 26.66% [3] Group 4 - Jincheng Pharmaceutical reported a 79.1% year-on-year decrease in net profit for the first three quarters, totaling 31.58 million yuan, with a revenue of 1.932 billion yuan, down 23.19% [4] - The third quarter revenue was 572 million yuan, a decline of 24.44% [4] Group 5 - WuXi AppTec plans to transfer 100% equity of two subsidiaries for a base price of 2.8 billion yuan, aiming to reinvest the funds into core business areas [5] - The sale of non-core assets is expected to enhance the company's competitiveness and potentially provide a short-term boost to stock prices [5]

Group 1 - The core point of the article is the performance and changes in the top holdings of the Yinhua CSI Innovation Drug Industry ETF, which reported a net value growth rate of 24.54% over the past year [1] - The fund has added new top holdings including Kanglong Chemical and Baile Tianheng, while increasing its stake in WuXi AppTec by 64.87 million shares, making it the largest holding [1] - The fund has exited from its previous top holdings, including Tigermed and Tonghua Golden Horse [1] Group 2 - The detailed data shows the number of shares held and market value for each of the top holdings, with WuXi AppTec holding 15.52 million shares valued at 1.74 billion and Kanglong Chemical holding 8.56 million shares valued at 306 million [1] - Other significant holdings include Hengrui Medicine, Changchun High-tech, and Kelun Pharmaceutical, with respective increases in shareholding [1] - The report indicates a strategic shift in the fund's portfolio, reflecting a focus on companies with strong growth potential in the pharmaceutical sector [1]

Core Viewpoint - The company, WuXi AppTec, reported strong financial performance for the first three quarters of 2025, with significant growth in various business segments, particularly in the CRDMO (Contract Research, Development, and Manufacturing) model, and announced a strategic asset sale to focus on core operations [1][26][29]. Financial Performance - As of September 30, 2025, the company had a backlog of orders amounting to RMB 59.88 billion, representing a year-on-year increase of 41.2% [5]. - The total revenue for the first three quarters of 2025 reached RMB 32.45 billion, with a year-on-year growth of 18.6% [5]. - Revenue from continuous operations grew by 22.5%, with chemical business revenue at RMB 25.98 billion, up 29.3% year-on-year [5][6]. Business Segments - The small molecule drug discovery segment delivered over 430,000 new compounds in the past year, with 250 molecules transitioning from research to development in the first three quarters of 2025 [6]. - The small molecule development and manufacturing (D&M) segment reported revenue of RMB 14.24 billion, a 14.1% increase year-on-year, with a total of 3,430 molecules in the pipeline [6]. - The TIDES (oligonucleotide and peptide) business saw revenue of RMB 7.84 billion, a remarkable growth of 121.1% year-on-year, with a 17.1% increase in backlog orders [7]. Strategic Decisions - The company announced the sale of 100% equity in two subsidiaries for a base price of RMB 2.8 billion to streamline operations and focus on its CRDMO business model [26][29]. - The board of directors approved the asset sale on October 24, 2025, with a unanimous vote, indicating strong internal support for the strategic shift [22][30]. Market Position - WuXi AppTec maintains a strong reputation in the global pharmaceutical R&D industry, adhering to the highest international quality standards and continuously optimizing its integrated CRDMO service model [2][3]. - The company has established a robust client base across various regions, including the US, Europe, and China, with significant revenue contributions from these markets [5].

Core Insights - WuXi AppTec reported a significant increase in performance, with a 18.61% year-on-year growth in revenue for the first three quarters of 2025, reaching 32.857 billion yuan, and a net profit of 12.076 billion yuan, marking an 84.84% increase year-on-year [2][3] Revenue Breakdown - The company achieved a total revenue of 32.857 billion yuan in the first three quarters of 2025, with the following contributions: - Chemical business revenue: 25.98 billion yuan, up 29.3% year-on-year - Small molecule D&M business revenue: 14.24 billion yuan, up 14.1% year-on-year - Testing business revenue: 4.17 billion yuan - Laboratory analysis and testing revenue: 2.96 billion yuan, up 2.7% year-on-year - Biological business revenue: 1.95 billion yuan, up 6.6% year-on-year [2] Client Revenue Distribution - Revenue from different regions for the first three quarters of 2025: - Revenue from U.S. clients: 22.15 billion yuan, up 31.9% year-on-year - Revenue from European clients: 3.84 billion yuan, up 13.5% year-on-year - Revenue from Chinese clients: 5.04 billion yuan, up 0.5% year-on-year - Revenue from other regions: 1.42 billion yuan, up 9.2% year-on-year [2] Business Strategy and Outlook - The growth in performance is attributed to the company's focus on the CRDMO business model, improved production efficiency, and increased capacity utilization from large-scale projects. The company expects a return to double-digit growth in continuous operations revenue, raising the growth forecast from 13%-17% to 17%-18% [3] - The overall revenue forecast for the year has been adjusted from 42.5 billion - 43.5 billion yuan to 43.5 billion - 44 billion yuan [3] Equity Transfer - The company announced a plan to transfer 100% equity of two subsidiaries for a base price of 2.8 billion yuan to Shanghai Shihe Rong Enterprise Management Consulting Co., Ltd. and Shanghai Shihe Mu Enterprise Management Consulting Co., Ltd. [3] - The acquiring parties are newly established companies under Hillhouse Capital, which have good financial status and creditworthiness [4]

本报记者 曹卫新 此前，药明康德曾在2024年年报中披露，预计公司2025年持续经营业务收入重回双位数增长，同比增长 10%至15%，公司整体收入达到415亿元至430亿元。2025年7月份，该公司在半年报中将持续经营业务 收入的增速从10%至15%上调为13%至17%，整体收入则从415亿元至430亿元上调为425亿元至435亿 元。 同日晚间，药明康德发布公告称，公司近日同高瓴投资旗下私募基金签署资产出售协议，拟将公司持有 的中国临床服务研究业务100%股权出售给对方，交易基准股权转让价格为28亿元。 药明康德相关负责人向《证券日报》记者表示，上述交易完成后，公司将持续聚焦CRDMO业务模式 （一种端到端的药物研发生产服务模型），专注药物发现、实验室测试及工艺开发和生产服务，并加速 全球化能力和产能的投放。 药明康德董事长兼首席执行官李革在接受《证券日报》记者采访时表示，得益于坚实的客户需求和公司 CRDMO业务模式的独特优势，药明康德2025年前三季度收入、利润、经营现金流均实现双位数强劲增 长，同时持续经营业务在手订单再创历史新高，达到599亿元。基于这一增长势头，公司进一步上调了 全年收入和自由现金 ...

Group 1: Company Performance Highlights - Ecovacs Robotics reported a significant increase in Q3 2025 revenue of 4.201 billion yuan, up 29.26% year-on-year, and a net profit of 438 million yuan, up 7160.87% [1] - Deep South Housing A achieved a revenue of approximately 898.85 million yuan in the first three quarters of 2025, a year-on-year increase of 331.66%, with a net profit of about 145.12 million yuan, up 2791.57% [1] - Antong Holdings reported Q3 2025 revenue of 2.152 billion yuan, an 18.85% increase year-on-year, and a net profit of 152 million yuan, up 2155.18% [2] - Sichuan Changhong's Q3 2025 revenue was 25.184 billion yuan, down 2.69% year-on-year, but net profit increased to 507 million yuan, up 690.83% [2] - Zhenghai Magnetic Materials reported a revenue of approximately 4.973 billion yuan for the first three quarters of 2025, a 30.54% increase, with a net profit of about 228 million yuan, up 20.46% [3] - Gold Mountain reported Q3 2025 revenue of 3.372 billion yuan, up 66.39% year-on-year, and a net profit of 951 million yuan, up 140.98% [4] Group 2: Corporate Actions and Strategic Moves - Yiyi Co. plans to acquire 100% equity of Gao Ye Jia, with the stock resuming trading on October 27 [6][8] - Ying Tang Zhi Kong is planning to issue shares to acquire assets, leading to a stock suspension starting October 27 [18][35] - Dream Jie Co. faced dissent from board member Chen Jie regarding the Q3 2025 report, raising concerns about its accuracy and completeness [9] - Drugmaker WuXi AppTec intends to sell 100% equity of two subsidiaries for 2.8 billion yuan to focus on its CRDMO business model [20][21] - Huayi Technology is planning to invest in a new project with a budget of approximately 266.65 million yuan for advanced manufacturing capabilities [22]